



## Company Overview

Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) is a leading global pharmaceutical company that delivers high-quality, patient-centric healthcare solutions to millions of patients every day. Headquartered in Israel, Teva is the world's largest generic medicines producer, leveraging its portfolio of more than 1,000 molecules to produce a wide range of generic products in nearly every therapeutic area. In specialty medicines, Teva has a world-leading position in innovative treatments for disorders of the central nervous system, including pain, as well as a strong portfolio of respiratory products. Teva integrates its generics and specialty capabilities in its global research and development division to create new ways of addressing unmet patient needs by combining drug development capabilities with devices, services and technologies. Teva's net revenues in 2015 amounted to \$19.7 billion. For more information, visit [www.tevapharm.com](http://www.tevapharm.com).

## Top and bottom line performance




## 12 Month Stock Performance (as of August 4)




## Net Revenues

(USD m)




## Operating Income (non GAAP<sup>1</sup>)

(USD m)




## Earnings Per Share (non GAAP<sup>1</sup>)

(USD)



## Dividends Per Share

(USD)



(1) See non GAAP reconciliation in our report for the (2<sup>th</sup> Quarter 2016)

## 2016 Priorities and Near Term Catalysts

### Defend

- Deliver our operational and financial targets for 2016
- Defend Copaxone® and Bendeka™

### Integrate & Extract Synergies

- Actavis Generics deal closing and integration
- Capturing all planned synergies
  - Rimsa
  - Teva-Takeda BV in Japan


### Build

- FDA Approvals:
  - SD-809 in HD
  - Vantrela® ER HC
- Key clinical milestones:
  - Submission: QVAR® BAI for asthma
  - PIII: SD-809 in tardive dyskinesia
  - PIII: TV-46763 for pain
  - PII: Pridopidine for HD


## Revenues by Markets and Segments

Q2 - 2016

Revenues by Market




Revenues by Segment



\* Other activities include our OTC business with P&G, distribution services primarily in Israel and Hungary, and sales of medical devices

## Profit\*\* by Segment

Q2 - 2016



\*\* Profit consists of gross profit, less S&M and R&D expenses related to the segment. Segment profitability does not include G&A expenses, amortization and certain other items.

## Teva Specialty pipeline

Phase 1	Phase 2	Phase 3	Registration
TV-46139 (abuse deterrent) Pain	TV-45070 Topical Neuropathic pain	TEV-48125 (anti CGRP) Chronic and episodic migraine	Vantrela ER abuse deterrent Hydrocodone US Pain
TEV-90105 (abuse deterrent) Pain	Laquinimod Multiple sclerosis (progressive forms)	TV-46763 (abuse deterrent) Pain	TEV-90109 Opioid addiction
SD-809 (deutetrabenazine) Tourette syndrome	Laquinimod Huntington disease	Laquinimod Multiple sclerosis (relapsing remitting)	Copaxone® 40mg 3w ROW Multiple sclerosis
SD-1077 (deuldopa) Parkinson's Disease	Pridopidine Huntington disease	SD-809 (deutetrabenazine) Tardive dyskinesia	SD-809 (deutetrabenazine) Huntington Disease
Fluticasone Salmeterol (MDI) EU Asthma, COPD	CEP-41750 (mesenchymal precursor cell) Acute myocardial infarction	QVAR® (BAI) US Asthma	Reslizumab IV Global Asthma - APPROVED in US*
SD-560 (deupirfenidone) Idiopathic pulmonary fibrosis		Reslizumab SC Global Asthma	TV-44663 Fluticasone Propionate RespiClick® US Asthma
TEV-46017 (tidal inhaler) COPD		CEP-41750 (mesenchymal precursor cell) Chronic heart failure	TV-44664 Fluticasone Salmeterol RespiClick® US Asthma
TEV-48107 (tidal inhaler) COPD			Fluticasone Salmeterol Spiromax EU Asthma, COPD
TEV-90110, TEV-90111, TEV- 90112, TEV-90113 HIV			

Note: Pipeline is correct as of April 2016. Phase 1 includes also projects designated for IND filing.  
\* US trade name: CINQAIR®